Enveric Biosciences (ENVB) Enterprise Value (2010 - 2026)

Enveric Biosciences has reported Enterprise Value for 17 years, with the latest figure at -$4.9 million in Q1 2026.

• Quarterly Enterprise Value fell 14.31% year-over-year to -$4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.9 million (down 14.31% YoY) and the FY2025 annual result came in at -$4.7 million, down 108.72% from the prior year.
• Enterprise Value declined to -$4.9 million in Q1 2026 per ENVB's latest filing, from -$4.7 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$2.2 million in Q4 2024 and troughed at -$21.7 million in Q1 2022.
• A 5-year average of -$8.0 million and a median of -$4.7 million in 2025 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value soared 86.41% in 2023, then slumped 108.72% in 2025.
• Over 5 years, Enterprise Value stood at -$16.8 million in 2022, then jumped by 86.41% to -$2.3 million in 2023, then increased by 2.05% to -$2.2 million in 2024, then tumbled by 108.72% to -$4.7 million in 2025, then fell by 4.94% to -$4.9 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$4.9 million, -$4.7 million, and -$3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.